VM
Vladimir Makarov
Founder at Rubicon Genomics
View Vladimir's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Founder
Present
Company Details
11-50 Employees
NOW PART OF TAKARA BIO USA, INC. -- Please visit the Takara Bio USA, Inc. company page for the latest updates: https://www.linkedin.com/company-beta/17509/ Rubicon Genomics was founded in 2000 by two University of Michigan faculty members, Dr. John Langmore and Dr. Vladimir Makarov, who wanted to advance the translation of human genetics “laboratory knowledge” into practical medical applications. Innovative technologies combined with strategic partnerships have established Rubicon products as industry leaders for pre-analytical sample processing and amplification. Core competencies including enzymology, nucleic acid chemistry, and manufacturing have served as engines for innovation, development of intellectual property, and ongoing product development. Partnerships with the academic community and with customers have fueled these engines, resulting in a robust pipeline of future products. Rubicon products "break the sample barriers" for customers by allowing use of less sample from a diverse set of sample sources. Each Rubicon kit is constructed for ease of use, robustness, and speed to results. Rubicon products are available for research use and can be purchased directly from Takara Bio, through our distributors, or from OEM partners.
Year Founded
2000
Social Media
LinkedinFacebookTwitter
Industry
Biotechnology Research, Analytical Services, Engineering & Consulting
HQ Location
4743 Venture Drive Ann Arbor, MI 48108, US
Keywords
Next Generation SequencingLibrary Preparation KitsNucleic Acid ChemistryDNA and RNA SequencingCell-free DNA SequencingSingle-cell SequencingLiquid Biopsy Sequencing
Discover More About Cleveland Clinic

Find verified contacts of Vladimir Makarov in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.